The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2, 1999, Pages 223-237

  Haire, William D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hematopoietic stem cell transplantation; HSCT; Infection; Malignancies; Medications; MODS; Multiple organ dysfunction syndrome

Indexed keywords

BACTERIAL PNEUMONIA; BRAIN HEMORRHAGE; CANCER PATIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0032962367     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994924     Document Type: Review

References (93)

1. Bone RC, Balk RA, Cerra FB. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Chest 1992;101:1644-1655
2. Bone RC. Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-687
3. Haire WD, Stephens LC, Ruby EI. Systemic inflammatory response syndrome and organ dysfunction in bone marrow transplantation. Blood 1995;86(SuppI I):214a(Abstr)
4. Schots R, Kaufman L, Van Reit I, et al. Monitoring of C-reactive protein after allogeneic bone marrow trasnplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998;22:79-85
5. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-3020
6. Clark JG, Hansen JA, Hertz MI, et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147:1601-1606
7. Haire WD, Ruby EI, Gordon BG, et al. Multiple organ dysfunction in bone marrow transplantation. JAMA 1995;274:1289- 1295
8. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267
9. Gordon BG, Tarantolo SR, Ruby EI, et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 1998;22:999-1003
10. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neuman FG. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997;23:379-385
11. Frenette PS, Moyna C, Hartwell DW, et al. Platelet-endothelial interactions in inflamed messenteric vessels. Blood 1998;91: 1318-1324
12. Faioni EM, Krachmalnicoff A, Bearman SJ, et al. Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993;81:3458-3462
13. Wingard JR, Mellits ED, Jones RJ, et al. Association of hepatic veno-occlusive disease with interstitial pneumonitits in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4:685-689
14. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked enzymuria after bone marrow transplantation: A correlate of veno-occlusive disease-induced "hepatorenal syndrome," J Am Soc Nephrol 1995;6:1655-1660
15. Nissen C, Tichelli A, Gratwohl A, et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 1988;72:2045-2047
16. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression, N Engl J Med 1988; 319:593-598
17. Hoekman K, Wagstaff J, van Groeningen CJ, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991;83:1546-1553
18. Conti JA, Scher JI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. Cancer 1992;70:2699-2702
19. Tolcher AW, Giusti RM, O'Shaughnessy JA, Cowan KH. Arterial thrombosis associated with granulocyte-macrophage colony- stimulating factor (GMCSF) administration in breast cancer patients treated with dose-intensive chemotherapy: A report of two cases. Cancer Invest 1995;13:188-192
20. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN 1995;19:75-79
21. Stephens LC, Haire WD, Schmit-Pokorny K, Kessinger A, Kotulak G. Granulocyte macrophage stimulating factor: High incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant 1993;11:51-54
22. Kadar JG, Arseniev L, Sosada M, et al. Prospective study of donor safety in growth factor mobilization and progenitor cell apheresis for allogeneic transplantation. Blood 1996;86(Suppl 1):579a(Abst)
23. Falanga A, Marchetti M, Oldani E, Giovanelli S, Barbui T. Changes of hemostatic parameters in healthy donors administered G-CSF for peripheral blood progenitor cell collection. Bone Marrow Transplant 1996;17(Suppl 2):S72(Abst)
24. Pollmacher T, Korth C, Mullingtion J, et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87:900-905
25. King J, Deboisblanc BP, Mason CM, et al. Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 1995;151:302-309
26. Link H, Boogacrts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992;80:2188-2195
27. Gordon BG, Haire WD, Ruby EI, et al. Factors predicting morbidity following hematopoietic stem cell transplantation. Bone Marrow Transplant 1997;19:497-501
28. Anasetti C, Anderson G, Appelbaum FR, et al. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 1993;82(Suppl 1):454a(Abstr)
29. Haire WD, Stephens LC, Ruby EI. Antithrombin III treatment of organ dysfunction during bone marrow transplantation - results of a pilot study. Blood 1996;88(Suppl 1):458a(Abstr)
30. Baker KS, Gordon BG, Gross TG, et al. Increased serum cytokines in hematopoietic stem cell transplant patients with multiple organ dysfunction syndrome (MODS). Blood 1997;90 (Suppl 1):224a(Abstr)
31. Meduri GU, Headly S, Kohler G, et al. Persistant elevations of inflammatory cytokines predict a poor outcome in ARDS. Chest 1995;107:1062-1073
32. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-778
33. van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-953
34. Neidhart R, Keel M, Steckholzer U, et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997;42:863-871
35. Hempel L, Korholz D, Nussbaum P, et al. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997; 20:365-368
36. Taylor FB, Chang A, Ferrel G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1993;78: 357-363
37. Kessler CM, Tang ZC, Jacobs HM. Supranormal antithrombin III (AT-III) levels achieved with AT concentrate (CON) reduce the mortality and morbidity of staphylococcus aureus (SA) - induced disseminated intravascular coagulation (DIC) in a guinea pig (GP) model. Blood 1995;86:379a(Abstr)
38. Redens TB, Leach WJ, Bogdnoff DA, Emerson TE. Synergistic protection from lung damage by combining antithrombin III and alpha-1-protease inhibitor in the E. coli endotoxic sheep model. Circ Shock 1988;26:15-26
39. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae-induced sepsis. Thromb Haemost 1993;69:98-102
40. Emerson TE, Fournel MA, Redens TB, Taylor FB. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989;87:3B-27S-3B-33S
41. Emerson TE, Fournel MA, Leach WJ, Redens TB. Protection against disseminated intravascular coagulation and death by antithrombin III in the Escherichia coli endotoxemic rat. Circ Shock 1987;21:113
42. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
43. Redens TB, Emerson TE. Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 1989;28:49-58
44. Murankami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647
45. Taylor FB, Chang A, Esmond CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
46. Uchiba M, Okajima K, Murakami K, et al. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995;74:1265-1270
47. Meyer J, Cox CS, Herndon DH, et al. Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993;21:84-89
48. Hardaway RM, Williams CH. Prevention of multiple organ failure with plasminogen activator. Curr Therapeutic Res 1991; 49:711-722
49. Palmoa MJ, Paramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs urokinase on PAI generation, fibrin deposits and mortality. Thromb Haemost 1995;74:1578-1582
50. Taylor FB, Chang AKC, Peer GT, et al. DEGR-factor X blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991;78:364-368
51. Fourrier F. Therapeutic applications of antithrombin concentrates in systemic disorders. Blood Coag Fibrinolysis 1998;9 (Suppl 2):S39-S45
52. Baudo F, Caimi TM, deCataldo F, et al. Antithrombin III replacement therapy in patients with sepsis and or postsurgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med 1998:24:336-342
53. Jochum M. Influence of highdose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32:19-32
54. Attal M, Huguet H, Huynh A. et al. Prevention of hepatic veno-occlusive disease after hone marrow transplantation by continnous infusion of low-dose heparin. Blood 1991;79:2834-2840
55. Demuynck H, Vandenberghe P, Verhoef GEG, Zachee P. Prevention of veno-occlusive disease (VOD) of the liver after marrow and blood progenitor cell transplantation: A prospective, randomized study of different prophylactic regimens. Blood 1995; 86:620a(Abstr)
56. Or R, Nagler A. Spilberg O, et al. Low molecular weight heparin (LMWH) may prevent veno-occlusive disease (VOD) and induce accelerated platelet recovery following hone marrow transplantation (BMT). Thromb Haemost 1995;73:974(Abstr)
57. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998:92:737-744
58. Bearman SI, Shuhart M, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for treatment of established severe veno-occlusive disease of the liver after hone marrow transplantation. Blood 1992;80:2458-2462
59. Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP. Recombinant tissue plasminogen activator (rt-PA) for venoocclusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994;46:194-198
60. Patton DF, Harper JL, Wooldridge TN, et al. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion of antithrombin III concentrate. Bone Marrow Transplant 1996;17:443-447
61. Morris JD, Harris RE, Hashmi R, et al. Antithrombin III for the treatment of chemotherapy induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997;20:871-878
62. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-387
63. Hussein MA, Long T, Zuccaro K. Platelet transfusion recovery and survival in stable bone marrow transplant patients: A prospective study. Blood 1995;86:103a(Abstr)
64. Benson K, Fields K, Hiemenz J, et al. The platelet-refractory bone marrow transplant patient: Prophylaxis and treatment of bleeding. Semin Oncol 1993;20:102-109
65. Fujimoto T, Suzuki H, Tanoue K, Fukushima Y, Yamazaki H. Cerebrovascular injuries induced by activation of platelets in vivo. Stroke 1985;16:245-250
66. Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome: Culprits or bystanders? Am Rev Respir Dis 1987;135:482-492
67. Grau GE, Lou J. TNF in vascular pathology: The importance of platelet endothelium interactions. Res Immunol 1993;144:355-369
68. Ferroni P, Speziale G, Ruvolo G, et al. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass - a possible correlation? Thromb Haemost 1998;80:58-64
69. Piguet PF, Vesin C, Ryser JE, et al. An effector role of platelets in systemic and local lipopolysaccharide induced toxicity in mice, medicated by a CD11-a and CD54-dependent interaction with endothelium. Infect Immunol 1993;61:4182-4187
70. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia:evidence for a fixed platelet requirement. Blood 1985;66:1105-1109
71. Goodnough LT, Kolodziej M, Ehlenbeck C, et al. A phase I study of safety and efficacy for infusible platelet membrane in patients. Blood 1995;86:610a(Abstr)
72. Scigliano E, Fruchtman S, Isola L, et al. Infusible platelet membrane (PM) for control of bleeding in thrombocytopenic patients. Blood 1995;86:446a(Abstr)
73. Demetri GD. Beyond supportive care: What are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? Blood 1993;82:2278-2280
74. Zurborn KH, Bruhn HD. Hypercoagulability and cytostatic tumor therapy. Blut 1986;53:179
75. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885-889
76. Edwards RL, Klaus M, Matthews E, et al. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990;89:25-28
77. Bone RC. Modulators of coagulation. Arch Intern Med 1992;152:1381-1389
78. Carvalho AC, Freeman NJ. How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoagulant conditions. J Crit III 1994;9:51-71
79. Bredbäcka S, Blombäck M, Winman B. Soluble fibrin: A predictor for the development and outcome of multiple organ failure. Am J Hematol 1994;46:289-294
80. Renesto P, Si-Tahar M, Moniatte M, et al. Specific inhibition of thrombin induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: Evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. Blood 1997;89:1944-1953
81. Gelehrter TD, Sznycer-Laszyk R. Thrombin induction of plasminogen activator inhibitor in cultured human endothelial cells. J Clin Invest 1986;77:165-169
82. Salat C, Holler E, Kolb H, et al. Plasminogen activator inhibitor I confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after hone marrow transplantation. Blood 1997;89:2184-2188
83. Lorant DE, Patel KD, McIntyre M, et al. Compression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991;115:223-234
84. Wright DG, Gallin JI. Secretory responses of human neutrophils: Exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol 1979;123:285-294
85. Yang JJ, Kettritz R, Falk RJ, Jennette JC, Gaido ML. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol 1996;149:1617-1626
86. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997:89:2429-2442
87. DeLa Cadena RA, Wachtfogel YT, Colman RW. Contact activation pathway: Inflammation and coagulation. In:Colmann RW, Hirsh I, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Co.; 1994:219-240
88. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). JAMA 1997;277:482-487
89. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984;4:116-122
90. Carreras E, Granena A, Navasa M, et al. On the reliability of the clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993;66:77-80
91. Folstein MF, Folstein SE, McHigh PR. "Mini-mental state" - a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
92. Anthony JC, LeResche L, Niaz U, von Korf MR, Folstein MF. Limits of the "mini-mental state" as a screening tool for dementia and delirium among hospital patients. Psychol Med 1982;12:397-408
93. Haire WD, Stephens LC, Kotulak CD, Ruby EI Gordon BG. Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1995;15:505-507